Director/PDMR Shareholding
Summary by AI BETAClose X
12 March 2026
Convatec Group Plc
("Convatec" or "the Company")
Director/PDMR Shareholding
The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").
1. Grant of Performance Share Awards
On 11 March 2026, the following conditional awards were granted to each of Jonny Mason, Chief Executive Officer and Fiona Ryder, Chief Financial Officer under the Convatec Group Omnibus Incentive Plan 2025 ("LTIP") in the form of Performance Share Awards ("PSA"). These PSA are due to vest on the third anniversary of grant at nil cost, conditional on the following performance conditions: organic revenue growth, three-year compound annualised growth in adjusted Earnings per Share, and three-year Relative Total Shareholder Return rank vs constituents of S&P Global Healthcare Equipment & Services index; and are subject to a two-year post vesting holding period:
Jonny Mason: 1,776,206
Fiona Ryder: 567,413
2. Grant of Deferred Bonus Awards
On the same date, the following conditional awards were granted to each of Jonny Mason and Fiona Ryder under the LTIP in the form of Deferred Bonus Awards ("DBA"). The DBA are due to vest on the third anniversary of grant at nil cost and are not subject to performance conditions:
Jonny Mason: 165,419
Fiona Ryder: 19,028
3. Grant of Restricted Share Awards
On the same date, the following conditional awards were granted to each of Jonny Mason and Fiona Ryder under the LTIP in the form of Restricted Share Awards ("RSA"). The RSA are due to vest on the third anniversary of grant at nil cost and are not subject to performance conditions:
Jonny Mason: 417,931
Fiona Ryder: 170,224
The preceding three-day average share price, closing on 10 March 2026, of £2.4167 was used in determining each of the awards made under the LTIP.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||
|
a) |
Name |
Jonny Mason |
||
|
2 |
Reason for the notification |
|||
|
a) |
Position/Status |
Chief Executive Officer and PDMR |
||
|
b) |
Initial notification/Amendment |
Initial notification |
||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||
|
a) |
Name |
Convatec Group Plc |
||
|
b) |
LEI |
213800LS272L4FIDOH92 |
||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary share of 10p each in Convatec Group Plc |
||
|
|
Identification code |
GB00BD3VFW73 |
||
|
b) |
Nature of the transaction |
a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.
|
||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
a. |
£0 |
1,776,206 |
||
|
b. |
£0 |
165,419 |
||
|
c. |
£0 |
417,931 |
||
|
d) |
Aggregated information - Aggregated volume - Price |
2,359,556 £0 |
||
|
e) |
Date of the transaction |
2026-03-11 |
||
|
f) |
Place of the transaction |
Outside a trading venue |
||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||
|
a) |
Name |
Fiona Ryder |
||
|
2 |
Reason for the notification |
|||
|
a) |
Position/Status |
Chief Financial Officer and PDMR |
||
|
b) |
Initial notification/Amendment |
Initial notification |
||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||
|
a) |
Name |
Convatec Group Plc |
||
|
b) |
LEI |
213800LS272L4FIDOH92 |
||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary share of 10p each in Convatec Group Plc |
||
|
|
Identification code |
GB00BD3VFW73 |
||
|
b) |
Nature of the transaction |
a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.
|
||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
a. |
£0 |
567,413 |
||
|
b. |
£0 |
19,028 |
||
|
c. |
£0 |
170,224 |
||
|
d) |
Aggregated information - Aggregated volume - Price |
756,665 £0 |
||
|
e) |
Date of the transaction |
2026-03-11 |
||
|
f) |
Place of the transaction |
Outside a trading venue |
||
Enquiries
James Kerton Company Secretary
Email: cosec@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 12 minutes ago Savills
- 31 minutes ago Everyman Media Group
- 1 hour ago Croda International
- 2 hours ago Diageo
- 2 hours ago IMI